Quick Answer
AC Immune SA reported Research And Development Expense of $56.44 million for the year ending 2025.
- AC Immune SA showed a decrease of -9.8% in Research And Development Expense from 2024 to 2025.
- This data is from AC Immune SA's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), AC Immune SA's Research And Development Expense has grown by 231.0%.
- Historical annual values: Fiscal year 2025: $56.44 million | Fiscal year 2024: $62.57 million | Fiscal year 2023: $54.61 million | Fiscal year 2022: $60.34 million | Fiscal year 2021: $62.28 million | Fiscal year 2020: $59.49 million | Fiscal year 2019: $50.43 million | Fiscal year 2018: $44.28 million | Fiscal year 2017: $32.66 million | Fiscal year 2016: $25.77 million | Fiscal year 2015: $17.05 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: